Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection-Reference-Cited by-同舟云学术

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

Published:2015-12-23 Issue:319 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Lynch Rebecca M.¹,Boritz Eli¹,Coates Emily E.¹,DeZure Adam¹,Madden Patrick¹,Costner Pamela¹,Enama Mary E.¹,Plummer Sarah¹,Holman Lasonji¹,Hendel Cynthia S.¹,Gordon Ingelise¹,Casazza Joseph¹,Conan-Cibotti Michelle¹,Migueles Stephen A.²,Tressler Randall³,Bailer Robert T.¹,McDermott Adrian¹,Narpala Sandeep¹,O’Dell Sijy¹,Wolf Gideon¹,Lifson Jeffrey D.⁴,Freemire Brandie A.⁴,Gorelick Robert J.⁴,Pandey Janardan P.⁵,Mohan Sarumathi⁵,Chomont Nicolas⁶,Fromentin Remi⁶,Chun Tae-Wook²,Fauci Anthony S.²,Schwartz Richard M.¹,Koup Richard A.¹,Douek Daniel C.¹,Hu Zonghui⁷,Capparelli Edmund⁸,Graham Barney S.¹,Mascola John R.¹,Ledgerwood Julie E.¹,

Affiliation:

1. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

2. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

3. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

4. Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.

5. Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.

6. Department of Microbiology, Infectiology, and Immunology, Université de Montréal, Faculty of Medicine, and Centre de Recherche du CHUM (Centre hospitalier de l’Université de Montréal), Montreal, Quebec H2X 0A9, Canada.

7. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

8. School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, CA 92110, USA.

Abstract

A single infusion with broadly neutralizing antibody VRC01 resulted in lowered plasma virus load in HIV-1–infected subjects.

Funder

NIH

National Cancer Institute/NIH

NIAID

Delaney AIDS Research Enterprise

VRC

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference68 articles.

1. Defeating AIDS—advancing global health

2. HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission

3. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

4. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

5. D. L. Bolton A. Pegu K. Wang K. McGinnis M. Nason K. Foulds V. Letukas S. D. Schmidt X. Chen J. P. Todd J. Lifson S. Rao N. L. Michael M. L. Robb J. R. Mascola R. A. Koup HIV-1 monoclonal antibodies suppress acute SHIV viremia and limit seeding of cell-associated viral reservoirs. J. Virol. JVI.02454-15 (2015).

Cited by 379 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy;Frontiers in Reproductive Health;2024-01-09

2. High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials;Nature Communications;2023-12-14

3. Broadly neutralizing antibodies targeting HIV: Progress and challenges;Clinical Immunology;2023-12

4. Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01;Nature Communications;2023-11-28

5. Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals;Nature Communications;2023-11-06